NEW YORK — Nimble Therapeutics and Svar Life Science said on Thursday that they have partnered on the development and commercialization of diagnostics for autoimmune diseases.
According to the companies, the alliance will initially focus on rheumatoid arthritis using biomarkers discovered using Nimble's human proteome immunoprofiling technology.
Under the terms of the deal, Nimble will receive an undisclosed upfront payment and stands to receive milestone payments and royalties on product sales. Additional terms were not disclosed.
"Partnering with Svar provides a strong commercial outlet for Nimble's discovery capabilities," Bradley Garcia, vice president of corporate development at Nimble, said in a statement.
Madison, Wisconsin-based Nimble, which was spun out of Roche a year ago, focuses on the discovery of novel peptide drugs using its parallel chemical synthesis platform. Malm, Sweden-based Svar — formerly Euro Diagnostica — develops assay technology for drug development and diagnostic applications.